164 related articles for article (PubMed ID: 25620096)
1. Dipeptidyl-peptidase IV (DPP IV/CD26)-activated prodrugs: a successful strategy for improving water solubility and oral bioavailability.
Velázquez S; de Castro S; Diez-Torrubia A; Balzarini J; Camarasa MJ
Curr Med Chem; 2015; 22(8):1041-54. PubMed ID: 25620096
[TBL] [Abstract][Full Text] [Related]
2. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.
Diez-Torrubia A; Cabrera S; Lambeir AM; Balzarini J; Camarasa MJ; Velázquez S
ChemMedChem; 2012 Apr; 7(4):618-28. PubMed ID: 22307932
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S
J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase IV-activated prodrugs of anti-varicella zoster virus bicyclic nucleoside analogues containing different self-cleavage spacer systems.
Diez-Torrubia A; Cabrera S; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
ChemMedChem; 2012 Sep; 7(9):1612-22. PubMed ID: 22887971
[TBL] [Abstract][Full Text] [Related]
6. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.
Diez-Torrubia A; García-Aparicio C; Cabrera S; De Meester I; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2010 Jan; 53(2):559-72. PubMed ID: 20000418
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
García-Aparicio C; Bonache MC; De Meester I; San-Félix A; Balzarini J; Camarasa MJ; Velazquez S
J Med Chem; 2006 Aug; 49(17):5339-51. PubMed ID: 16913724
[TBL] [Abstract][Full Text] [Related]
8. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
Balzarini J; Andersson E; Schols D; Proost P; Van Damme J; Svennerholm B; Horal P; Vahlne A
Int J Biochem Cell Biol; 2004 Sep; 36(9):1848-59. PubMed ID: 15183349
[TBL] [Abstract][Full Text] [Related]
9. Efficient conversion of tetrapeptide-based TSAO prodrugs to the parent drug by dipeptidyl-peptidase IV (DPPIV/CD26).
García-Aparicio C; Diez-Torrubia A; Balzarini J; Lambeir AM; Velázquez S; Camarasa MJ
Antiviral Res; 2007 Nov; 76(2):130-9. PubMed ID: 17675255
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity.
Jacotot E; Callebaut C; Blanco J; Krust B; Neubert K; Barth A; Hovanessian AG
Eur J Biochem; 1996 Jul; 239(2):248-58. PubMed ID: 8706727
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
[TBL] [Abstract][Full Text] [Related]
12. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption.
Rumondor ACF; Dhareshwar SS; Kesisoglou F
J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl-peptidase IV-beta--further characterization and comparison to dipeptidyl-peptidase IV activity of CD26.
Blanco J; Nguyen C; Callebaut C; Jacotot E; Krust B; Mazaleyrat JP; Wakselman M; Hovanessian AG
Eur J Biochem; 1998 Sep; 256(2):369-78. PubMed ID: 9760177
[TBL] [Abstract][Full Text] [Related]
14. Is prodrug design an approach to increase water solubility?
Sanches BMA; Ferreira EI
Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients.
Korom S; De Meester I; Stadlbauer TH; Chandraker A; Schaub M; Sayegh MH; Belyaev A; Haemers A; Scharpé S; Kupiec-Weglinski JW
Transplantation; 1997 May; 63(10):1495-500. PubMed ID: 9175816
[TBL] [Abstract][Full Text] [Related]
16. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
Krise JP; Charman WN; Charman SA; Stella VJ
J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
[TBL] [Abstract][Full Text] [Related]
17. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.
Aytac U; Dang NH
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Mar; 4(1):11-8. PubMed ID: 15032621
[TBL] [Abstract][Full Text] [Related]
18. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors.
Augustyns K; Bal G; Thonus G; Belyaev A; Zhang XM; Bollaert W; Lambeir AM; Durinx C; Goossens F; Haemers A
Curr Med Chem; 1999 Apr; 6(4):311-27. PubMed ID: 10101215
[TBL] [Abstract][Full Text] [Related]
19. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
Jana S; Mandlekar S; Marathe P
Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding.
Yu DM; Slaitini L; Gysbers V; Riekhoff AG; Kähne T; Knott HM; De Meester I; Abbott CA; McCaughan GW; Gorrell MD
Scand J Immunol; 2011 Feb; 73(2):102-11. PubMed ID: 21198750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
